Funding for this research was provided by:
National Institute for Health Research (RJ112/N027)
Biotechnology and Biological Sciences Research Council (BB/R012504/1, BBS/E/F/000PR10348, BBS/E/F/000PR10349, BBS/E/F/000PR10351, BBS/E/F/000PR10352, BB/CCG1860/1)
Innovate UK (TS/S00887X/)
guy's & st thomas' charity (TCF190910)
Received: 16 April 2021
Accepted: 14 October 2021
First Online: 17 November 2021
: Ethical approval for the use of surplus anonymized samples taken as part of routine care without written informed consent for the purpose of novel diagnostic development, including sequencing and data handling, was granted by the UK Health Research Authority/Research Ethics Committee (UK HRA and REC reference 20/SC/0310). All aspects of this study involving human participants and human samples were conducted in accordance with the 1964 Helsinki Declaration and its later amendments.
: Not applicable
: JOG has received speaking honoraria, consultancy fees, in-kind contributions or research funding from Oxford Nanopore, Simcere, Becton-Dickinson and Heraeus Medical. The remaining authors declare that they have no competing interests.